NCT00019097 2024-03-04
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
7 trialsNCT00004198 2023-12-27
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT00006478 2023-09-18
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Terminated
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00093522 2013-12-19
Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004249 2013-06-19
Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed